Combination of deferasirox and deferoxamine in clinical practice: An alternative scheme of chelation in thalassemia major patients

Blood Cells, Molecules, and Diseases

Volumn 53, Issue 3, 2014, Pages 164-167

  Cassinerio, E ^a   Orofino, N ^a   Roghi, A ^b   Duca, L ^a   Poggiali, E ^c   Fraquelli, M ^a   Zanaboni, L ^a   Cappellini, M D ^a,c  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Cardiac iron overload; Chelation therapy; Deferasirox; Deferoxamine; Thalassemia major

Indexed keywords

DEFERASIROX; DEFEROXAMINE; FERRITIN; HEMOGLOBIN; BENZOIC ACID DERIVATIVE; TRIAZOLE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ADVERSE OUTCOME; AGRANULOCYTOSIS; ARTICLE; AUDIOMETRY; CARDIOVASCULAR MAGNETIC RESONANCE; CHELATION THERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL PRACTICE; CONCENTRATION (PARAMETERS); DIAGNOSTIC IMAGING EQUIPMENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELASTOGRAPHY; EYE EXAMINATION; FEMALE; FOLLOW UP; HEPATIC MAGNETIC RESONANCE; HUMAN; IRON INTAKE; IRON OVERLOAD; LIVER IRON CONCENTRATION; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THALASSEMIA MAJOR; BETA THALASSEMIA; COMPLICATION; DRUG COMBINATION; TREATMENT OUTCOME;

ADULT; BENZOATES; BETA-THALASSEMIA; CHELATION THERAPY; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRON OVERLOAD; MALE; TREATMENT OUTCOME; TRIAZOLES;

EID: 84904725111     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2014.04.006     Document Type: Article

References (19)

1. Pennell D.J., Udelson J.E., Arai A.E., Bozkurt B., Cohen A.R., Galanello R., Hoffman T.M., Kiernan M.S., Lerakis S., Piga A., Porter J.B., Walker J.M., Wood J., American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association, Circulation (2013) 128 281-308. Circulation 2013, 128:e203. Erratum in.
2. Porter J.B., Elalfy M.S., Taher A.T., Aydinok Y., Chan L.L., Lee S.H., Sutcharitchan P., Habr D., Martin N., El-Beshlawy A. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Ann. Hematol. 2013, 92:211-219.
3. Cappellini M.D., Bejaoui M., Agaoglu L., Canatan D., Capra M., Cohen A., Drelichman G., Economou M., Fattoum S., Kattamis A., Kilinc Y., Perrotta S., Piga A., Porter J.B., Griffel L., Dong V., Clark J., Aydinok Y. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5years' follow-up. Blood 2011, 118:884-893.
4. Pennell D.J., Porter J.B., Cappellini M.D., Chan L.L., El-Beshlawy A., Aydinok Y., Ibrahim H., Li C.K., Viprakasit V., Elalfy M.S., Kattamis A., Smith G., Habr D., Domokos G., Roubert B., Taher A. Deferasirox for up to 3years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica 2012, 97:842-848.
5. Lai M.E., Grady R.W., Vacquer S., Pepe A., Carta M.P., Bina P., Sau F., Cianciulli P., Maggio A., Galanello R., Farci P. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cells Mol Dis 2010 Aug 15, 45(2):136-139.
6. Voskaridou E., Komninaka V., Karavas A., Terpos E., Akianidis V., Christoulas D. Combination therapy of deferasirox and deferoxamine shows improvements in markers of iron overload in a patient with beta-thalassemia major and severe iron burden. Transfusion 2013, (Jul 9). 10.1111/trf.12335.
7. Grady R.W., Galanello R., Randolph R.E., Kleinert D.A., Dessi C., Giardina P.J. Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine. Haematologica 2013, 98:129-135.
8. Lal A., Porter J., Sweeters N., Ng V., Evans P., Neumayr L., Kurio G., Harmatz P., Vichinsky E. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol. Dis. 2013, 50:99-104.
9. Otto-Duessel M., Brewer C., Gonzales I., Nick H., Wood J.C. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. Acta Haematol. 2008, 120:123-128.
10. Jetsrisuparb A., Komvilaisak P., Wiangnon S., Jetsrisuparb C. Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2years. J. Pediatr. Hematol. Oncol. 2010, 32:400-403.
11. Evans R., Kayyali R., Hider R.C., Eccleston J., Porter J.B. Mechanism for the shuttling of plasma non-transferrin-bound-iron (NTBI) onto deferoxamine by deferiprone. Transl. Res. 2010, 156:55-67.
12. Glickstein H., El R.B., Link G., et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 2006, 108:3195-3203.
13. Wood J.C., Enriquez C., Ghugre N., Tyzka J.M., et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle-cells disease patients. Blood 2005, 106:1460-1465.
14. Fraquelli M., Rigamonti C., Casazza G., Conte D., Donato M.F., Ronchi G., et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007, 56:968-973.
15. Wood J.C. History and current impact of cardiac magnetic resonance imaging on the management of iron overload. Circulation 2009, 120:1937-1939.
16. Pennell D.J., Berdoukas V., Karagiorga M., Ladis V., Piga A., Aessopos A., Gotsis E.D., Tanner M.A., Smith G.C., Westwood M.A., Wonke B., Galanello R. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006, 107:3738-3744.
17. Tanner M.A., GAlanello R., Dessi C., Smith G.C., Westwood M.A., Agus A., Pibiri M., Nair S.V., Walker J.M., Pennel D.J. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J. Cardiovasc. Magn. Reson. 2008, 126:736-742.
18. Voskaridou D., Christoulas D., Terpos E. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. Br. J. Haematol. 2011, 154:654-665.
19. Deugnier Y., Turlin B., Ropert M., Cappellini M.D., Porter J.B., Giannone V., et al. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3years. Gastroenterology 2011, 141:1202-1211.